Klotho Neurosciences, Inc. (KLTO)
NASDAQ: KLTO · Real-Time Price · USD
0.1744
+0.0083 (5.00%)
At close: May 12, 2025, 4:00 PM
0.1485
-0.0259 (-14.85%)
After-hours: May 12, 2025, 7:59 PM EDT
Company Description
Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders.
Its lead gene therapy product candidates comprise KLTO-101 for the treatment or prevention of Alzheimer’s disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig’s disease.
The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024.
Klotho Neurosciences, Inc. is based in Omaha, Nebraska.
Klotho Neurosciences, Inc.
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Joseph Sinkule |
Contact Details
Address: 13576 Walnut Street, Suite A Omaha, Nebraska 68144 United States | |
| Phone | 833 931 6330 |
| Website | klothoneuro.com |
Stock Details
| Ticker Symbol | KLTO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001907223 |
| ISIN Number | US49876K1034 |
| Employer ID | 86-2727441 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Joseph Sinkule Pharm.D. | Founder, Chief Executive Officer, Chairman of the Board and Secretary |
| Jeffrey LeBlanc | Chief Financial Officer |
| Peter J. Moriarty | Chief Operating Officer and Chief Business Officer |
| Dr. Shalom Z. Hirschman M.D. | Medical Advisor and Director |
| Dr. Miguel Chillon Rodriguez | Chief Scientific Advisor and Consultant |
| Dr. Bradford A. Navia M.D., Ph.D. | Chief Medical Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 5, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 21, 2025 | 8-K | Current Report |
| Apr 4, 2025 | 8-K | Current Report |
| Apr 1, 2025 | 8-K | Current Report |
| Mar 31, 2025 | 10-K | Annual Report |
| Mar 27, 2025 | PRE 14A | Other preliminary proxy statements |
| Feb 24, 2025 | 8-K | Current Report |
| Feb 13, 2025 | 424B3 | Prospectus |
| Feb 10, 2025 | EFFECT | Notice of Effectiveness |
| Feb 6, 2025 | UPLOAD | Filing |